- United States
- /
- Biotech
- /
- NasdaqCM:SLS
SELLAS Life Sciences Group Full Year 2022 Earnings: EPS Misses Expectations
SELLAS Life Sciences Group (NASDAQ:SLS) Full Year 2022 Results
Key Financial Results
- Net loss: US$41.3m (loss widened by 100% from FY 2021).
- US$2.13 loss per share (further deteriorated from US$1.34 loss in FY 2021).
All figures shown in the chart above are for the trailing 12 month (TTM) period
SELLAS Life Sciences Group Earnings Insights
Looking ahead, revenue is forecast to grow 51% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in the US.
Performance of the American Biotechs industry.
The company's shares are down 1.5% from a week ago.
Risk Analysis
You still need to take note of risks, for example - SELLAS Life Sciences Group has 6 warning signs (and 4 which don't sit too well with us) we think you should know about.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NasdaqCM:SLS
SELLAS Life Sciences Group
A late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States.
Flawless balance sheet slight.
Market Insights
Community Narratives
